Biofrontera publishes interim report for the 3rd quarter of 2013
(Thomson Reuters ONE) -
Biofrontera AG /
Biofrontera publishes interim report for the 3rd quarter of 2013
. Ad hoc announcement according to § 15 WpHG. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Leverkusen, Germany - Biofrontera AG (DSE: B8F) has today published its interim
report for the third quarter of 2013 on the corporate webpage. The report
focuses on the company's development; detailed financial figures are not being
published at the end of this period.
The ongoing commercial year is characterized by the marketing of Ameluz(®),
Biofrontera's prescription drug for the treatment of actinic keratosis. Since
February 2012 Ameluz(®) is distributed in Germany through Biofrontera's own
sales force. Biofrontera achieved a significant increase in revenues from
product sales compared to the same period in the previous year. In the first
nine months of 2013, 15,633 tubes of Ameluz(®) were sold, compared to 9,250
tubes last year. Product sales for the first nine months 2013 were TEUR 1.868,
compared to TEUR 1,103 in the comparable period of the previous year,
representing a 69% increase. In the first months of the year 2012 license deals
were closed for several European countries, resulting in one-time payments of
TEUR 1,550 in addition to the product sales. The marketing agreements closed
this year covered smaller countries and did not include upfront payments since
higher transfer prices were agreed upon.
During the reporting period Ameluz(®) was launched in Spain by our regional
representative Allergan in an impressive educational event for Spanish
dermatologists in Madrid. Ameluz(®) is reimbursed by 100% in Spain. Spain is one
of the largest PDT-markets in Europe and Biofrontera expects positive effects
for its further revenue growth outside Germany.
The clinical studies for the expansion of the approved indications for Ameluz(®)
and the registration in the USA were also initiated in the reporting period.
Patient recruitment has already started in three clinical trials, while the
fourth trial is in the approval process. Total research and development expenses
amounted to TEuro 1,950 in the first nine months of the year.
About Biofrontera AG
Biofrontera Pharma GmbH is a wholly-owned subsidiary of Biofrontera AG. The
Biofrontera group aims at attending and treating the skin, recognizing the
aesthetic needs of a person's visual reflection. Biofrontera is listed at the
regulated market of the Frankfurt stock exchange under the symbol B8F and the
ISIN number DE0006046113.
www.biofrontera.com
This press release contains forward-looking statements based on the currently
held beliefs and assumptions of the management of Biofrontera AG, which are
expressed in good faith and, in their opinion, reasonable. Forward-looking
statements involve known and unknown risks, uncertainties and other factors,
which may cause the assumptions expressed or implied in this press release to be
faulty. Given these risks, uncertainties and other factors, recipients of this
document are cautioned not to place undue reliance on the forward-looking
statements. Biofrontera AG disclaims any obligation to update these forward-
looking statements to reflect future events or developments.
For further information please contact:
Thomas Schaffer, CFO
+ 49 214 87632 0
+ 49 214 87632 90
t.schaffer(at)biofrontera.com
Biofrontera AG
Hemmelrather Weg 201
D- 51377 Leverkusen, Germany
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Biofrontera AG via Thomson Reuters ONE
[HUG#1741768]
Unternehmensinformation / Kurzprofil:
Datum: 08.11.2013 - 09:23 Uhr
Sprache: Deutsch
News-ID 314354
Anzahl Zeichen: 4546
contact information:
Town:
Leverkusen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 164 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Biofrontera publishes interim report for the 3rd quarter of 2013"
steht unter der journalistisch-redaktionellen Verantwortung von
Biofrontera AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
